Alzheimer’s drug from Eisai and Biogen gets FDA accelerated approval
Trials showed €25,000 a year drug slowed rate of cognitive decline in patients with early Alzheimer’s by 27% compared to a placebo.
Eisai
Biogen CEO to step down as company pulls back on Alzheimer’s drug
Future of Aduhelm was in doubt after Medicare restricted coverage to clinical trials
US regulators approve Alzheimer’s drug from Biogen
Many scientists opposed approval of controversial treatment, saying it did not work
Nikkei closes at near three-decade high as Biden edges closer to win
Investors hope a gridlock in US congress would be able to stall major policy changes
European stocks end week with gains for tech and telecoms
Dublin market closed marginally higher with food stocks leading the way
Alzheimer’s drug hopes see Biogen shares surge 27%
Pharma group resurrects pipeline therapy it abandoned as ineffective earlier this year
Trade concerns fail to halt modest market gains
Iseq overall index again underperformed European peers, up 0.12 per cent
Trade concerns fail to halt modest market gains
Market report: Iseq overall index again underperformed European peers, up 0.12 per cents
Nikkei tops 20,000 for the first time in 15 years
Japan’s main index ends the week 2.4% higher after rally
Counting the cost of cancer as drug rationing introduced
The cost of powerful new drugs is pushing health budgets to the limit
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Election 2024
Full general election coverage including analysis and results for all 43 constituencies
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices